

Performance in Initiating Clinical Trials Q2 2020-2021
First participant recruited

Ethics Committee Number	IRAS Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site confirmed by Sponsor	Date Site confirmed	Date Site Ready to Start	Date of First Patient Recruited	Source of Delay	Comments
19/NE/0233	239794	Randomised placebo controlled trial of pramipexole addition to mood stabilisers for treatment-resistant bipolar depression.	08/10/2019	11/12/2019	04/09/2019	13/12/2019	20/12/2019	09/01/2020			
19/EE/0314	269954	Evaluating the Community Areas of Sustainable Care and Dementia Excellence (CASCADE) Model of Care	14/11/2019	06/02/2020	05/02/2020	02/03/2020	02/03/2020	05/03/2020			
19/EM/0326	249015	NEON (Narrative Experiences Online) study: trials of an online intervention	06/01/2020	06/01/2020	13/12/2019	16/01/2020	03/03/2020	12/03/2020	07/04/2020		
19/LO/1667	271363	Clinical and cost-effectiveness of a New psychological intervention to support Independence in Dementia (NIDUS) for family carers and people living with dementia in their own homes: A randomised controlled trial	15/01/2020	15/01/2020	13/01/2020	28/04/2020	11/05/2020	12/05/2020	21/05/2020		
20/SC/0158	281958	Platform Randomised trial of INterventions against COVID-19 In older peoPLE	30/06/2020	30/06/2020	26/03/2020						
20/SW/0086	1003226	A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)	02/07/2020	02/07/2020	01/07/2020	24/08/2020	24/08/2020				
19/LO/1354	262807	Internet-delivered Cognitive Therapy (iCT) for young people with Post-Traumatic Stress Disorder (PTSD) - feasibility randomised controlled trial	10/07/2020	10/07/2020	07/01/2020	17/09/2020	17/09/2020	17/09/2020			
19/EE/0177	260067	HOMESIDE: A home-based family caregiver-delivered music intervention for people living with dementia: a randomised controlled trial	02/07/2020	02/07/2020	14/08/2019	18/08/2020	22/09/2020	22/09/2020			
20/NW/0399	288793	A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1 Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom	24/09/2020	24/09/2020	23/09/2020	08/10/2020	08/10/2020	09/10/2020			